16 research outputs found
Long term management of obstructive sleep apnea and its comorbidities
Obstructive sleep apnea (OSA) is a worldwide highly prevalent disease associated with systemic consequences,
including excessive sleepiness, impairment of neurocognitive function and daytime performance, including driving
ability. The long-term sequelae of OSA include and increase risk for cardiovascular, cerebrovascular and metabolic
syndrome disorders that ultimately lead to premature death if untreated. To ensure optimal long-term outcomes, the
assessment and management of OSA should be personalized with the involvement of the appropriate specialist. Most
studies have demonstrated inmediate improvement in daytime somnolence and quality of life with CPAP and other
therapies, but the effect of long-term treatment on mortality is still under debate. Currently, the long-term
management of OSA should be based on a) identifying physiological or structural abnormalities that are treatable at
the time of patient evaluation and b) comprehensive lifestyle interventions, especially weight-loss interventions, which
are associated with improvements in OSA severity, cardiometabolic comorbidities, and quality of life. In long-term
management, attention should be paid to the clinical changes related to a potential reoccurrence of OSA symptoms
and it is also necessary to monitor throughout the follow up how the main associated comorbidities evolve
Forkhead Box P3 Methylation and Expression in Men with Obstructive Sleep Apnea
BACKGROUND: Epigenetic changes in obstructive sleep apnea (OSA) have been proposed as a mechanism for end-organ vulnerability. In children with OSA, Forkhead Box P3 (FOXP3) DNA methylation were associated with inflammatory biomarkers; however, the methylation pattern and its effect in the expression of this gene have not been tested in adults with OSA. METHODS: Plasma samples from subjects without comorbid conditions other than OSA were analyzed (the Epigenetics Status and Subclinical Atherosclerosis in Obstructive Sleep Apnea (EPIOSA) Study: NCT02131610). In 16 patients with severe OSA (Apnea-Hypopnea Index-AHI- > 30 events/h) and seven matched controls (AHI 10) and 31 controls, we quantified FOXP3 protein expression by ELISA and gene expression by quantitative real-time PCR. C-reactive protein (CRP) and plasma Treg cells were also evaluated. RESULTS: Neither the levels of the promoter nor the TSDR demethylated region were different between controls and patients with OSA, whether they were grouped by normal or high CRP. FOXP3 protein and mRNA expression did not differ between groups. CONCLUSIONS: FOXP3 methylation or its expression is not altered in adults with OSA, whatever their inflammatory status
Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea
Background: Hypoxia can reduce the levels of soluble receptor for advanced glycation end-products (sRAGE), a new anti-infammatory biomarker of COPD. We assessed sRAGE in patients with hypoxia-related diseases such as COPD, OSA and OSA-COPD overlap.
Methods: Plasma levels of sRAGE were measured in 317 subjects at baseline (57 heathy nonsmokers [HNS], 84 healthy smokers [HS], 79 OSA, 62 COPD and 35 OSA-COPD overlap patients) and in 294 subjects after one year of follow-up (50 HNS, 74 HS, 77 OSA, 60 COPD and 33 overlap).
Results: After adjusting for age, sex, smoking status and body mass index, sRAGE levels showed a reduction in OSA (− 12.5%, p=0.005), COPD (− 14.8%, p<0.001) and OSA-COPD overlap (− 12.3%, p=0.02) compared with HNS. There were no diferences when comparing sRAGE plasma levels between overlap patients and those with OSA or COPD alone. At follow-up, sRAGE levels did not change signifcantly in healthy subjects, COPD and OSA or OSA-COPD overlap nontreated with continuous positive airway pressure (CPAP). Moreover, in patients with OSA and OSA-COPD overlap who were treated with CPAP, sRAGE increased signifcantly.
Conclusions: The levels of sRAGE are reduced in COPD and OSA. Treatment with CPAP appears to improve sRAGE levels in patients with OSA who also had COPD.The EPIOSA study (NCT02131610) was supported by Grants Number PI12/02175, PI15/01940 and PI18/01524 from the Instituto Salud Carlos III, Spanish Ministry of Health, Madrid, Spain and the European Regional Development Fund (FEDER) and by a Grant Number 01/2010 from the SADAR-Pneumo Aragón, Zaragoza, Spain
Somatotypes trajectories during adulthood and their association with COPD phenotypes
Rationale: Chronic obstructive pulmonary disease (COPD) comprises distinct phenotypes, all
characterised by airflow limitation.
Objectives: We hypothesised that somatotype changes – as a surrogate of adiposity – from early adulthood
follow different trajectories to reach distinct phenotypes.
Methods: Using the validated Stunkard’s Pictogram, 356 COPD patients chose the somatotype that best
reflects their current body build and those at ages 18, 30, 40 and 50 years. An unbiased group-based
trajectory modelling was used to determine somatotype trajectories. We then compared the current
COPD-related clinical and phenotypic characteristics of subjects belonging to each trajectory.
Measurements and main results: At 18 years of age, 88% of the participants described having a lean or
medium somatotype (estimated body mass index (BMI) between 19 and 23 kg·m−2
) while the other 12% a
heavier somatotype (estimated BMI between 25 and 27 kg·m−2
). From age 18 onwards, five distinct
trajectories were observed. Four of them demonstrating a continuous increase in adiposity throughout
adulthood with the exception of one, where the initial increase was followed by loss of adiposity after age
40. Patients with this trajectory were primarily females with low BMI and DLCO (diffusing capacity of the
lung for carbon monoxide). A persistently lean trajectory was seen in 14% of the cohort. This group had
significantly lower forced expiratory volume in 1 s (FEV1), DLCO, more emphysema and a worse BODE
(BMI, airflow obstruction, dyspnoea and exercise capacity) score thus resembling the multiple organ loss
of tissue (MOLT) phenotype.
Conclusions: COPD patients have distinct somatotype trajectories throughout adulthood. Those with the
MOLT phenotype maintain a lean trajectory throughout life. Smoking subjects with this lean phenotype in
early adulthood deserve particular attention as they seem to develop more severe COPD
Sleep Apnoea and Cancer: Is There a Relationship?
In recent decades, obstructive sleep apnoea (OSA) has come to represent a major public health problem due to its prevalence and its health consequences. Although the association between OSA and cardiovascular morbidity and mortality is well recognized, its role as a promoter for the development and extension of neoplasms is less known. In recent years, intensive research on the subject has been developed. Bench and animal studies demonstrate
how sleep fragmentation and intermittent hypoxia, characteristic phenomena of OSA, are capable of inducing tumorigenesis in various organs and cell lines. However, clinical and population-based epidemiological studies are showing certain contradictory results. These topics are reviewed and discussed in this paper
Long term management of obstructive sleep apnea and its comorbidities
Obstructive sleep apnea (OSA) is a worldwide highly prevalent disease associated with systemic consequences,
including excessive sleepiness, impairment of neurocognitive function and daytime performance, including driving
ability. The long-term sequelae of OSA include and increase risk for cardiovascular, cerebrovascular and metabolic
syndrome disorders that ultimately lead to premature death if untreated. To ensure optimal long-term outcomes, the
assessment and management of OSA should be personalized with the involvement of the appropriate specialist. Most
studies have demonstrated inmediate improvement in daytime somnolence and quality of life with CPAP and other
therapies, but the effect of long-term treatment on mortality is still under debate. Currently, the long-term
management of OSA should be based on a) identifying physiological or structural abnormalities that are treatable at
the time of patient evaluation and b) comprehensive lifestyle interventions, especially weight-loss interventions, which
are associated with improvements in OSA severity, cardiometabolic comorbidities, and quality of life. In long-term
management, attention should be paid to the clinical changes related to a potential reoccurrence of OSA symptoms
and it is also necessary to monitor throughout the follow up how the main associated comorbidities evolve
Symptomatic smokers without COPD have physiological changes heralding the development of COPD
Background COPD is a major health problem, mainly due to cigarette smoking. Most studies in COPD are dedicated to fully developed COPD in older subjects, even though development of COPD may start soon after smoking initiation. Therefore, there is a need to diagnose this "early disease" by detecting the initial events responsible for ultimate development of COPD.Methods Measurement of maximum mid expiratory flow between 25 and 75% of vital capacity (MMEF) in a routine spirometry, which detects small airways disease, was used to investigate if MMEF abnormalities in smokers without COPD (noCOPD) would relate to respiratory symptoms and identify smokers that might progress to COPD. For this purpose we studied 511 smokers, 302 COPD and 209 noCOPD, followed long term with spirometry including MMEF, diffusing capacity of the lung for carbon monoxide (D-LCO), 6-min walk test (6MWT), Medical Research Council Dyspnoea Scale and COPD Assessment Test. Three spirometries V1,V2 and V3 (5 +/- 2.5 and 10 +/- 4 years apart from V1) were performed to assess functional decline and development of COPD.Results 65% of noCOPD had an abnormal MMEF (<80%) and 38% an abnormal D-LCO. The NoCOPD with MMEF <80% group performed worse in the 6MWT (p=0.01), was more dyspnoeic (p=0.01) and had higher prevalence of chronic bronchitis than the noCOPD with MMEF>80% group (p=0.04). 21% of noCOPD with MMEF <80% and 2.7% with MMEF>80% developed COPD by V3 (p=0.0004).Conclusions The MMEF, a functional test available in a routine spirometry, can detect early lung abnormalities and identify the subset of symptomatic smokers with pathological changes that might lead to COPD
Chronic Bronchitis Affects Outcomes in Smokers without Chronic Obstructive Pulmonary Disease (COPD)
Background. Chronic bronchitis (CB) importantly affects outcomes in smokers with COPD, but the effects on smokers without COPD are less well known and less emphasized. The aim of our study was to investigate the possible effects of CB on clinical outcomes in smokers without COPD (noCOPD) and compare them with the effects in smokers with COPD (COPD). Methods. For that purpose, we studied 511 smokers, 302 with and 209 without COPD, followed for 10 years in an academic COPD ambulatory setting. Chronic bronchitis was defined as the presence of cough and sputum production for at least 3 months in each of two consecutive years. All subjects underwent clinical and functional examination with spirometry, diffusion capacity (DLco), 6-min walking test (6MWT), mMRC Dyspnoea Scale, COPD Assessment Test (CAT), and recording of annual frequency of exacerbations. All-cause mortality during follow-up was recorded. Results. 27% of noCOPD and 45% of COPD had CB. noCOPD with CB had lower FEV1 and DLco, worse 6MWT, more dyspnoea, a higher number of exacerbations and lower survival than noCOPD without CB. CB did not affect FEV1 decline in noCOPD but it significantly did in COPD. Conclusions. The presence of chronic bronchitis in smokers without COPD will significantly affect symptoms, quality of life, and survival, underlining the importance of recognizing the condition and managing it accordingly
SMAD4 Expression in Monocytes as a Potential Biomarker for Atherosclerosis Risk in Patients with Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) patients are at special risk of suffering atherosclerosis, leading to major cardiovascular diseases. Notably, the transforming growth factor (TGF-β) plays a crucial role in the development and progression of atherosclerosis. In this context, the central regulator of TGF-β pathway, SMAD4 (small mother against decapentaplegic homolog 4), has been previously reported to be augmented in OSA patients, which levels were even higher in patients with concomitant cardiometabolic diseases. Here, we analyzed soluble and intracellular SMAD4 levels in plasma and monocytes from OSA patients and non-apneic subjects, with or without early subclinical atherosclerosis (eSA). In addition, we used in vitro and ex vivo models to explore the mechanisms underlying SMAD4 upregulation and release. Our study confirmed elevated sSMAD4 levels in OSA patients and identified that its levels were even higher in those OSA patients with eSA. Moreover, we demonstrated that SMAD4 is overexpressed in OSA monocytes and that intermittent hypoxia contributes to SMAD4 upregulation and release in a process mediated by NLRP3. In conclusion, this study highlights the potential role of sSMAD4 as a biomarker for atherosclerosis risk in OSA patients and provides new insights into the mechanisms underlying its upregulation and release to the extracellular space
Nocturnal Hypoxemia and CT Determined Pulmonary Artery Enlargement in Smokers
Background: Pulmonary artery enlargement (PAE) detected using chest computed tomography (CT) is associated with poor outcomes in chronic obstructive pulmonary disease (COPD). It is unknown whether nocturnal hypoxemia occurring in smokers, with or without COPD, obstructive sleep apnoea (OSA) or their overlap, may be associated with PAE assessed by chest CT. Methods: We analysed data from two prospective cohort studies that enrolled 284 smokers in lung cancer screening programs and completing baseline home sleep studies and chest CT scans. Main pulmonary artery diameter (PAD) and the ratio of the PAD to that of the aorta (PA:Ao ratio) were measured. PAE was defined as a PAD ≥ 29 mm in men and ≥27 mm in women or as a PA:Ao ratio > 0.9. We evaluated the association of PAE with baseline characteristics using multivariate logistic models. Results: PAE prevalence was 27% as defined by PAD measurements and 11.6% by the PA:Ao ratio. A body mass index ≥ 30 kg/m2 (OR 2.01; 95%CI 1.06–3.78), lower % predicted of forced expiratory volume in one second (FEV1) (OR 1.03; 95%CI 1.02–1.05) and higher % of sleep time with O2 saturation < 90% (T90) (OR 1.02; 95%CI 1.00–1.03), were associated with PAE as determined by PAD. However, only T90 remained significantly associated with PAE as defined by the PA:Ao ratio (OR 1.02; 95%CI 1.01–1.03). In the subset group without OSA, only T90 remains associated with PAE, whether defined by PAD measurement (OR 1.02; 95%CI 1.01–1.03) or PA:Ao ratio (OR 1.04; 95%CI 1.01–1.07). Conclusions: In smokers with or without COPD, nocturnal hypoxemia was associated with PAE independently of OSA coexistence